Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients

Annals of Oncology

Volumn 12, Issue 8, 2001, Pages 1097-1106

  Venturini, M ^a   Michelotti, A ^c   Papaldo, P ^b   Del Mastro, L ^a   Bergaglio, M ^a   Lionetto, R ^a   Lunardi, G ^a   Sguotti, C ^d   Frevola, L ^d   Donati, S ^c   Rosso, R ^a   Cognetti, F ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Instituto Regina Elen   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d Aventis Pharma   (Italy)

Author keywords

Breast cancer; Docetaxel; Epirubicin; Phase I

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; METHYLPREDNISOLONE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG TOXICITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; TAXOIDS;

EID: 17944368538     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011663821703     Document Type: Article

References (28)

1. Clinical evaluation of adriamycin, a new antitumor antibiotic
2. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
3. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
4. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC
5. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
6. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
7. New cytotoxic drugs in treatment of breast cancer
8. Reporting results of cancer treatment
9. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
10. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
11. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I-II Study of the National Cancer Institute of Canada-clinical Trials Group
12. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
13. A phase I-II study of docetaxel and epirubicin in advanced breast cancer
14. Combination of two active drugs: Epirubicin-docetaxel (taxotere) in advanced breast cancer: Preliminary results
15. Phase II study of docetaxel and epirubicin as first line chemotherapy in metastatic breast cancer
16. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
17. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study
18. Typhlitis associated with docetaxel treatment
19. Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
20. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
21. Dose finding study and pharmacokinetics of epirubicin and paclitaxel over three hours. A regimen with high activity and low cardiotoxicity in advanced breast cancer
22. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety
23. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
24. Doxorubicin and taxotere a pharmacokinetic study of the combination in advanced breast cancer
25. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol
26. Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations
27. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients